Mn Services Vermogensbeheer B.V. lessened its stake in CrowdStrike Holdings, Inc. (NASDAQ:CRWD – Free Report) by 2.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 87,600 shares of the company’s stock after selling 2,500 shares during the quarter. Mn Services Vermogensbeheer B.V.’s holdings in CrowdStrike were worth $24,569,000 at the end of the most recent quarter.
Other institutional investors have also bought and sold shares of the company. Abich Financial Wealth Management LLC purchased a new position in CrowdStrike in the 2nd quarter valued at approximately $25,000. Oakworth Capital Inc. bought a new stake in shares of CrowdStrike during the 3rd quarter valued at $28,000. Tsfg LLC lifted its holdings in CrowdStrike by 593.3% during the 3rd quarter. Tsfg LLC now owns 104 shares of the company’s stock worth $29,000 after purchasing an additional 89 shares in the last quarter. Family Firm Inc. bought a new position in CrowdStrike in the 2nd quarter worth about $30,000. Finally, Castleview Partners LLC purchased a new position in CrowdStrike during the 3rd quarter valued at about $32,000. Hedge funds and other institutional investors own 71.16% of the company’s stock.
Analyst Upgrades and Downgrades
A number of equities analysts have recently commented on the stock. JMP Securities restated a “market outperform” rating and issued a $400.00 price objective on shares of CrowdStrike in a research report on Monday. Morgan Stanley reiterated an “overweight” rating and issued a $325.00 price objective on shares of CrowdStrike in a research report on Monday, September 9th. Hsbc Global Res upgraded CrowdStrike from a “hold” rating to a “strong-buy” rating in a research report on Friday, August 30th. Oppenheimer lowered their price target on CrowdStrike from $450.00 to $365.00 and set an “outperform” rating on the stock in a report on Thursday, August 29th. Finally, Wells Fargo & Company cut their price objective on CrowdStrike from $435.00 to $350.00 and set an “overweight” rating for the company in a report on Monday, July 22nd. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, thirty-one have assigned a buy rating and three have given a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $328.74.
CrowdStrike Stock Performance
Shares of CRWD opened at $298.88 on Tuesday. The company has a quick ratio of 1.90, a current ratio of 1.90 and a debt-to-equity ratio of 0.26. The stock has a market cap of $73.26 billion, a P/E ratio of 433.16, a P/E/G ratio of 20.07 and a beta of 1.10. The business’s 50 day moving average price is $285.51 and its 200-day moving average price is $307.96. CrowdStrike Holdings, Inc. has a 52 week low of $183.60 and a 52 week high of $398.33.
CrowdStrike (NASDAQ:CRWD – Get Free Report) last issued its quarterly earnings results on Wednesday, August 28th. The company reported $1.04 earnings per share for the quarter, beating the consensus estimate of $0.97 by $0.07. CrowdStrike had a return on equity of 8.44% and a net margin of 4.84%. The firm had revenue of $963.87 million during the quarter, compared to the consensus estimate of $958.27 million. During the same period last year, the company earned $0.06 earnings per share. The company’s revenue was up 31.7% on a year-over-year basis. Equities research analysts anticipate that CrowdStrike Holdings, Inc. will post 0.52 earnings per share for the current fiscal year.
Insider Buying and Selling
In other CrowdStrike news, CAO Anurag Saha sold 1,683 shares of the stock in a transaction on Monday, September 23rd. The stock was sold at an average price of $297.28, for a total transaction of $500,322.24. Following the sale, the chief accounting officer now directly owns 38,962 shares in the company, valued at approximately $11,582,623.36. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other CrowdStrike news, CAO Anurag Saha sold 1,683 shares of the company’s stock in a transaction dated Monday, September 23rd. The shares were sold at an average price of $297.28, for a total transaction of $500,322.24. Following the transaction, the chief accounting officer now owns 38,962 shares in the company, valued at approximately $11,582,623.36. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, President Michael Sentonas sold 10,776 shares of the business’s stock in a transaction that occurred on Monday, September 23rd. The shares were sold at an average price of $297.28, for a total transaction of $3,203,489.28. Following the transaction, the president now directly owns 400,390 shares of the company’s stock, valued at $119,027,939.20. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 103,212 shares of company stock worth $30,529,413 in the last three months. Insiders own 4.34% of the company’s stock.
CrowdStrike Company Profile
CrowdStrike Holdings, Inc provides cybersecurity solutions in the United States and internationally. Its unified platform offers cloud-delivered protection of endpoints, cloud workloads, identity, and data. The company offers corporate endpoint and cloud workload security, managed security, security and vulnerability management, IT operations management, identity protection, SIEM and log management, threat intelligence, data protection, security orchestration, automation and response and AI powered workflow automation, and securing generative AI workload services.
Featured Stories
- Five stocks we like better than CrowdStrike
- How to buy stock: A step-by-step guide for beginners
- Intel: Is Now the Time to Be Brave?
- Best Stocks Under $5.00
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- What is a Dividend King?
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Receive News & Ratings for CrowdStrike Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CrowdStrike and related companies with MarketBeat.com's FREE daily email newsletter.